李奧國際精準健康
LEO INTERNATIONAL PRECISION HEALTH

Leo International Precision Health AG approves cash capital increase excluding subscription rights

22 May 2026

Leo International Precision Health AG / Keyword: Capital measures / Capital increase
Leo International Precision Health AG approves cash capital increase excluding subscription rights
22. May 2026 / 20:04 CET/CEST

Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014, transmitted by GlobeNewswire.

The management board and the supervisory board of Leo International Precision Health AG (ISIN DE0005490601, WKN 549060, ticker symbol LEOW, „Company") resolved today to increase the Company's share capital by approximately 4.2 % against cash contributions through the issuance of 24,000 new no-par bearer shares of the Company ("New Shares"), utilizing a portion of the authorized capital 2025 and excluding shareholders' subscription rights ("Capital Increase"). Upon entry of the completion of the capital increase in the commercial register, the Company's share capital will increase from the current EUR 576,000.00 by EUR 24,000.00 to EUR 600,000.00.

The New Shares were subscribed exclusively by Hsiao-Hsuan "Leo" Wang, New Taipei, Taiwan, as the majority shareholder and Chair of the Supervisory Board of the Company, at a subscription price of EUR 25.00 per New Share. The subscription price is about 25 % above the closing price of the Company's shares on the regulated market of the Frankfurt Stock Exchange on 21 May 2026.

The gross proceeds from the capital increase amount to EUR 600,000.00. The Company intends to use the net proceeds from the capital increase primarily to strengthen its equity base and for the purposes of its ongoing business operations.

Upon entry of the completion of the capital increase in the Commercial Register, the New Shares will be admitted to trading on the regulated market of the Frankfurt (General Standard) and Düsseldorf Stock Exchange without a prospectus.

Important Notice:
This document and the information contained herein are for informational purposes only and do not constitute a prospectus or an offer to sell or a solicitation of an offer to buy securities of the Company in the United States of America ("U.S.") or in any other jurisdiction. This publication may not be distributed, published, or disseminated in the U.S., Australia, Canada, or Japan. The Company's securities may not be offered or sold in the U.S. without registration or an exemption from registration under the U.S. Securities Act of 1933, as amended ("Securities Act"). The Company's securities have not been and will not be registered under the Securities Act or the applicable securities laws of Australia, Canada, or Japan. There will be no public offering of the Company's shares.

The distribution of this announcement may be restricted by law in certain jurisdictions, and persons, who come into possession of documents or other information referred to herein, should inform themselves of and comply with such restrictions. Failure to comply with these restrictions may constitute a violation of the securities laws of such a jurisdiction.

End of Inside Information

Language	English
Company	Leo International Precision Health AG Am Klopferspitz 19 82152 Planegg / Martinsried Germany
Phone	+49895527580
Fax	
Email	ir@liphag.com
Homepage	https://www.liphag.com
LEI	529900R5095181VD8H48
Listed	— DE0005490601, DE - Frankfurt Exchange, Boerse Frankfurt - Regulierter Markt, 549060; DE - Dusseldorf Stock Exchange, Boerse Duesseldorf - Regulierter Markt, 549060;
Indices	